Conditions: Alzheimer Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 63
Healthy volunteers: yes

Brief summary:
The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813. Study participants will be healthy or will have mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild to moderate AD.

There will be seven groups of study participants. Five groups will receive a single dose of LY3002813 or placebo (no drug), followed by up to 4 multiple doses of LY3002813 or placebo given as an injection into a vein. Approximately 12 weeks will pass between the single dose and the first multiple dose. One group of participants will receive a single dose of LY3002813 given as an injection under the skin. One group of participants will receive a single dose of LY3002813 given as an injection into a vein.

Detailed description:

Arms:
arm 1: 0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV) arm 2: 0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV arm 3: 1 mg/kg single dose LY3002813 given once by IV infusion. arm 4: 1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV arm 5: 3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV arm 6: 10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV arm 7: Placebo given once, then every 4 weeks for up to 16 weeks IV arm 8: Up to 3 mg/kg LY3002813 given once subcutaneously (SC) arm 9: Up to 3mg/kg LY3002813 given once intravenously (IV)

Interventions: intervention 1: LY3002813-IV intervention 2: LY3002813-SC intervention 3: Placebo-IV
Intervention descriptions: intervention 1: Administered IV intervention 2: Administered SC intervention 3: Administered IV

Protocol document: